(NASDAQ: AQST) Aquestive Therapeutics's forecast annual revenue growth rate of 34.42% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.59%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Aquestive Therapeutics's revenue in 2025 is $44,132,000.On average, 6 Wall Street analysts forecast AQST's revenue for 2025 to be $4,596,760,955, with the lowest AQST revenue forecast at $4,407,784,667, and the highest AQST revenue forecast at $5,075,933,022. On average, 6 Wall Street analysts forecast AQST's revenue for 2026 to be $6,310,013,005, with the lowest AQST revenue forecast at $3,674,815,950, and the highest AQST revenue forecast at $7,499,217,352.
In 2027, AQST is forecast to generate $11,488,661,370 in revenue, with the lowest revenue forecast at $8,735,790,426 and the highest revenue forecast at $14,659,374,345.